Genome & Co.

Genome & Co.

KKRX:314130
2,920.00
KRW
-45.00
(-1.52%)
-1,209.61EPS
138.70BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.38
2.86
7.82
16.78
500.34
506.24
910.73
784.11
685.16
Basic EPS, GAAP
-2,780
-5,281
-1,596
-1,269
-1,841.5
-1,680.81
-660.2
-205
-1,158.57
Free Cash Flow per Basic Share
-530.35
-688.78
-1,037.94
-1,098.71
-1,805.57
-1,815.4
-673.48
-602.25
-511.59
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1,033.71
-2,411.33
4,187.69
3,296.3
3,419.08
2,095.34
1,527.27
2,896.95
1,866.85
Tangible Book Value per Share
-1,036.68
-2,431.35
4,004.5
2,057.68
2,341.16
1,238.47
806.31
2,417.96
1,432.85
Basic Weighted Avg Shares
11
16
19
27
28
28
30
31
36
Sales/Revenue/Turnover
4
46
151
451
14,085
14,296
27,745
24,587
24,461
Operating Margin (%)
-148,126.55
-30,155.63
-17,683.84
-7,997.2
-408.34
-385.37
-87.22
-118.9
-119.33
Depreciation Expense
352
570
1,464
2,591
9,462
8,272
7,447
6,672
6,020
Net Income, GAAP
-30,297
-84,669
-30,732
-34,117
-51,838
-47,466
-20,112
-6,428
-41,361
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-727,116.15
-184,731.34
-20,409.23
-7,560.62
-368.05
-332.02
-72.49
-26.14
-169.09
Working Capital
-12,688
-35,921
108,272
71,952
105,769
68,167
62,115
29,445
44,900
LT Debt
41
1,132
1,179
5,243
4,267
12,764
12,395
2,326
1,974
Total Equity
-15,927
-39,308
115,083
113,400
150,544
113,517
99,065
114,577
81,295
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-33.42
-54.83
-60.06
-36.86
-8.66
-57.75

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
16,641
25,006
22,837
LT Borrowings
- -
- -
- -
LT Finance Leases
2,326
2,164
1,974
Preferred Equity and Hybrid Capital
4,693
4,872
4,872
Shares Outstanding
35
35
36
Market Capitalization
240,064
275,306
138,702

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
52,294
78,278
79,088
Cash, Cash Equivalents & STI
36,830
60,771
64,301
Accounts Receivable, Net
1,855
1,461
2,277
Inventories
5,979
7,731
9,704
Total Current Liabilities
22,849
52,571
34,189
Payables & Accruals
- -
- -
- -
ST Debt
16,641
25,006
22,837
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.92%
15.66%
Free Cash Flow
- -
10.56%
-7.96%
Net Income, GAAP
- -
-14.23%
-68.04%
Sales/Revenue/Turnover
- -
661.03%
-11.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,261
11,628
4,623
7,233
27,745
2025
6,354
5,809
6,558
5,867
24,587
2026
5,782
6,254
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-271.5
26.5
-278
-218.45
-660.2
2025
-227
-227
-242.13
421.53
-205
2026
-182.17
-997
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Full Time Employees
96
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Seongnam-si South Korea
IPO Date
Dec 26, 2018
Business
Genome & Company is a clinical-stage biotechnology company that discovers, develops, and commercializes antibody-drug conjugates (ADCs), novel target immuno-oncology biologics, microbiome-based therapeutics, and microbiome-derived consumer healthcare products, while providing specialized contract development and manufacturing organization (CDMO) services. Founded in 2015 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company operates research, clinical, and manufacturing facilities across South Korea and the United States, targeting global biopharmaceutical markets and consumer healthcare sectors. Genome & Company utilizes its proprietary GNOCLE drug discovery platform to translate clinical data into novel therapeutic targets, operating across four primary business segments: Antibody-Drug Conjugates and Novel Biologics, encompassing GENA-111, an ADC candidate targeting CD239 for solid tumors, and GENA-104 (EP0089), a first-in-class monoclonal antibody targeting contactin-4 (CNTN4) for refractory oncology indications; Microbiome Therapeutics, comprising GEN-001, an oral microbiome therapeutic candidate developed for immuno-oncology combination treatments including PD-L1-positive gastric cancer, and SB-121, a bacterial formulation for central nervous system disorders such as autism spectrum disorder developed via subsidiary Scioto Biosciences; Contract Development and Manufacturing Organization (CDMO) Services, offering end-to-end process development, analytical testing, and cGMP manufacturing for live biotherapeutic products (LBPs) and microbial therapeutics through U.S.-based operating subsidiaries List Biological Laboratories, Inc. and List Biotherapeutics, Inc.; and Consumer Healthcare and Cosmetics, marketing functional derma-cosmetic products formulated with patented microbiome ingredients under the proprietary commercial brand UIQ. In recent corporate developments, Genome & Company executed a strategic operational pivot to concentrate capital and clinical resources on its high-value ADC and novel antibody pipeline. In May 2024, the company entered into an exclusive global licensing agreement valued at up to 425.6 million USD (586 billion KRW) with Swiss biopharmaceutical firm Debiopharm to develop and commercialize GENA-111 (designated Debio 0633) utilizing Debiopharm Multilink technology. In February 2025, Genome & Company finalized an exclusive worldwide licensing and development agreement with UK-based Ellipses Pharma for the clinical advancement of GENA-104. Concurrently, the company completed Phase 2 combination trials for GEN-001 with avelumab in gastric cancer while deprioritizing new early-stage standalone microbiome programs to optimize R&D expenditure, and accelerated international distribution and retail expansion for its UIQ consumer brand across key Asian markets.